Please login to the form below
macular oedema
This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.
CHMP recommends eight new medicines for EU approval
Byoovis is designed for the treatment of wet age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to
Latest news
-
Bicycle Therapeutics looks to raise $86m with IPO
The lead molecule of this partnership is THR-149, a novel plasma kallikrein inhibitor, for the treatment of diabetic macular oedema.
-
After Lucentis setback, Novartis trumpets data on follow-up drug
The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD), ... In addition to nAMD, Novartis
-
Regeneron and Bayer drop AMD combination
Abandon plans after disappointing phase II trial results. Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival ... advance the duo into phase III in
-
Lucentis claims speedy FDA review for myopia complication
in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.
-
NICE backs Bayer’s Eylea as first-line BRVO treatment
This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin
Bicycle Therapeutics looks to raise $86m with IPO
After Lucentis setback, Novartis trumpets data on follow-up drug
Regeneron and Bayer drop AMD combination
Lucentis claims speedy FDA review for myopia complication
More from news
Approximately 8 fully matching, plus 37 partially matching documents found.
Latest Intelligence
-
Diagnosed Anywhere
The system creates an immediate, reliable assessment for diabetic retinopathy, including macular oedema, during a routine office visit in a primary care setting.
-
Medius Deal Watch table for February 2015
Majority acquisition. 380. Pfenex/ Hospira. PF582 - LUCENTIS biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema.
-
Allergan and taking a specialised approach
spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.
Diagnosed Anywhere
Medius Deal Watch table for February 2015
Allergan and taking a specialised approach
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
October 2020: diversity and inclusion in clinical trials round-up
macular oedema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat Black patients vs white patients. ... This is the first study looking at race as a factor in the treatment of diabetic macular oedema
October 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- New data from Moderna supports COVID boosters
- $47.5m research centre to seek genetic insights into disease
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Nicky Hutchens appointed as deputy managing director at Four Health
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- bluebird bio gears up for split
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- If the shoe fits
- Initiative Health welcomes Life Sciences by Stickyeyes
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
